Aetna Applauds FDA Decision Maintaining Access to Affordable Medication for Pregnant Women at Risk for Premature Deliveries
March 30 2011 - 5:36PM
Business Wire
The United States Food and Drug Administration today announced
that specialty pharmacies can continue compounding 17P
(hydroxyprogesterone caproate) based on a valid prescription for an
individually identified patient.
“Today's FDA decision is an outstanding win for women and their
at-risk babies who may have lost access to a safe
and cost-effective treatment to help prevent preterm
birth. Aetna has championed the need to provide 17P at an
affordable price so that pregnant women would not
face a 100-fold increase
in treatment cost. The FDA's decision is well-reasoned
and helps keep quality health care more affordable,” said Lonny
Reisman, M.D., Aetna chief medical officer.
About Aetna
Aetna (NYSE: AET) is one of the nation’s leading diversified
health care benefits companies, serving approximately 35.3 million
people with information and resources to help them make better
informed decisions about their health care. Aetna offers a broad
range of traditional, voluntary and consumer-directed health
insurance products and related services, including medical,
pharmacy, dental, behavioral health, group life and disability
plans, and medical management capabilities and health care
management services for Medicaid plans. Our customers include
employer groups, individuals, college students, part-time and
hourly workers, health plans, governmental units,
government-sponsored plans, labor groups and expatriates. For more
information, see www.aetna.com. To learn more about Aetna's
innovative online tools, visit www.aetnatools.com.
Aetna (NYSE:AET)
Historical Stock Chart
From May 2024 to Jun 2024
Aetna (NYSE:AET)
Historical Stock Chart
From Jun 2023 to Jun 2024